We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

90 hedge funds and large institutions have $156M invested in BioSpecifics Technologies Corp. in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 48 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 16

16% more capital invested

Capital invested by funds: $135M → $156M (+$21.2M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

1% less funds holding

Funds holding: 9190 (-1)

Holders
90
Holders Change
-1
Holders Change %
-1.1%
% of All Funds
2.4%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
48
Reduced
16
Closed
9
Calls
Puts
Net Calls
Net Calls Change

BSTC Hedge Fund Activity: Q2 2016 in Review

90 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q2 2016, worth a combined $156M — up 16% from $135M a quarter earlier.

Fund positioning in BSTC was balanced in Q2 2016: 9 funds opened new positions, 9 closed out, 48 added to existing stakes and 16 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $4.35M. The largest seller was Abdiel Capital Advisors, exiting entirely with an estimated $11.8M sold.

  • 90 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q2 2016, down from 91 in Q1 2016.
  • Funds reported $156M of BioSpecifics Technologies Corp. stock for Q2 2016, up 16% quarter-over-quarter.
  • 9 funds opened new BioSpecifics Technologies Corp. positions in Q2 2016 and 9 closed out, a net change of 0 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q2 2016 was Eagle Asset Management, an estimated $4.35M added.
  • The largest BioSpecifics Technologies Corp. seller in Q2 2016 was Abdiel Capital Advisors, an estimated $11.8M sold.

Based on aggregated 13F filings for Q2 2016.